You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The impact of cancer therapy on cognition in the elderly
|
|---|---|
| Published in |
Frontiers in Pharmacology, January 2013
|
| DOI | 10.3389/fphar.2013.00048 |
| Pubmed ID | |
| Authors |
Victoria Mandilaras, Doreen Wan-Chow-Wah, Johanne Monette, Francine Gaba, Michèle Monette, Linda Alfonso |
| Abstract |
Cancer and cancer therapy-related cognitive impairment (formerly known as chemobrain or chemo-fog) are often described in the literature. In the past, studies have failed to prove the existence of cancer therapy-related cognitive dysfunction. However, more recently, prospective trials have shown that patients undergoing chemotherapy do display impairment in specific cognitive domains. Aging confers an increased risk of developing cancer, as well as cognitive impairment. The Geriatric Oncology clinic of the Segal Cancer Centre, Jewish General Hospital in Montreal was founded in 2006 to address the unique needs of older cancer patients. We will describe two cases of cancer therapy-related cognitive impairment from our Geriatric Oncology clinic. The first case is that of a 75 year old male diagnosed with stage III non-small cell lung carcinoma who complained of forgetfulness since starting carboplatin-paclitaxel. The second case is that of a 65 year old female diagnosed with stage I, estrogen-receptor-positive breast cancer who had undergone lumpectomy followed by adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy, radiation therapy and was on exemestane when she was evaluated. We will also briefly review the literature of cancer therapy-related cognitive impairment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 2% |
| Unknown | 51 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 21% |
| Researcher | 7 | 13% |
| Student > Master | 7 | 13% |
| Student > Doctoral Student | 5 | 10% |
| Student > Bachelor | 4 | 8% |
| Other | 7 | 13% |
| Unknown | 11 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 29% |
| Psychology | 7 | 13% |
| Neuroscience | 6 | 12% |
| Agricultural and Biological Sciences | 3 | 6% |
| Sports and Recreations | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 14 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2013.
All research outputs
#20,190,878
of 22,707,247 outputs
Outputs from Frontiers in Pharmacology
#9,919
of 15,936 outputs
Outputs of similar age
#248,737
of 280,717 outputs
Outputs of similar age from Frontiers in Pharmacology
#92
of 167 outputs
Altmetric has tracked 22,707,247 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,936 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,717 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 167 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.